Evidence map›Paper›PMID 38971768›Full record

ArticleScientific reports2024

Combination immunohistochemistry for CK5/6, p63, GATA6, and HNF4a predicts clinical outcome in treatment-naïve pancreatic ductal adenocarcinoma.

Takahiro Shibayama, Akimasa Hayashi, Masao Toki, Keiichiro Kitahama, Yu-Jui Ho, Kenichiro Kato, Takahiro Yamada, Sho Kawamoto, Komei Kambayashi, Kazushige Ochiai and 7 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Takahiro ShibayamaDepartment of Pathology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan.
Akimasa HayashiDepartment of Pathology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan. hayashia@ks.kyorin-u.ac.jp.
Masao TokiDepartment of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.
Keiichiro KitahamaDepartment of Pathology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan.
Yu-Jui HoCancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kenichiro KatoDepartment of Pathology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan.
Takahiro YamadaDepartment of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.
Sho KawamotoDepartment of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.
Komei KambayashiDepartment of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.
Kazushige OchiaiDepartment of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.
Koichi GondoDepartment of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.
Naohiro OkanoDepartment of Medical Oncology, Faculty of Medicine, Kyorin University, Tokyo, Japan.
Jerry P MelchorThe David M. Rubenstein Center for Pancreatic Cancer Research, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Christine A Iacobuzio-DonahueThe David M. Rubenstein Center for Pancreatic Cancer Research, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yoshihiro SakamotoDepartment of Surgery, Kyorin University School of Medicine, Tokyo, Japan.
Tadakazu HisamatsuDepartment of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.
Junji ShibaharaDepartment of Pathology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan. jshiba@ks.kyorin-u.ac.jp.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Grant-in-Aid for Scientific Research 22K06968NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Although sequence-based studies show that basal-like features lead to worse prognosis and chemotherapy-resistance compared to the classical subtype in advanced pancreatic ductal adenocarcinoma (PDAC), a surrogate biomarker distinguishing between these subtypes in routine diagnostic practice remains to be identified. We aimed to evaluate the utility of immunohistochemistry (IHC) expression subtypes generated by unsupervised hierarchical clustering based on staining scores of four markers (CK5/6, p63, GATA6, HNF4a) applied to endoscopic ultrasound-guided fine needle aspiration biopsy (EUS-FNAB) materials. EUS-FNAB materials taken from 190 treatment-naïve advanced PDAC patients were analyzed, and three IHC patterns were established (Classical, Transitional, and Basal-like pattern). Basal-like pattern (high co-expression of CK5/6 and p63 with low expression of GATA6 and HNF4a) was significantly associated with squamous differentiation histology (p < 0.001) and demonstrated the worst overall survival among our cohort (p = 0.004). IHC expression subtype (Transitional, Basal vs Classical) was an independent poor prognosticator in multivariate analysis [HR 1.58 (95% CI 1.01-2.38), p = 0.047]. Furthermore, CK5/6 expression was an independent poor prognostic factor in histological glandular type PDAC [HR 2.82 (95% CI 1.31-6.08), p = 0.008]. Our results suggest that IHC expression patterns successfully predict molecular features indicative of the Basal-like subgroup in advanced PDAC. These results provide the basis for appropriate stratification for therapeutic selection and prognostic estimation of advanced PDAC in a simplified manner.

Indexed as

Biomarkers, TumorCarcinoma, Pancreatic DuctalGATA6 Transcription FactorHepatocyte Nuclear Factor 4ImmunohistochemistryPancreatic NeoplasmsAdultAgedAged, 80 and overEndoscopic Ultrasound-Guided Fine Needle AspirationFemaleHumansKeratin-5Keratin-6MaleMiddle AgedBiomarkers, TumorGATA6 protein, humanGATA6 Transcription FactorHepatocyte Nuclear Factor 4HNF4A protein, humanKeratin-5Keratin-6TP63 protein, humanTranscription FactorsTumor Suppressor ProteinsExpressional subtypesImmunohistochemistryPancreatic ductal adenocarcinomaSurrogate biomarker

Identifiers

PMID38971768
PMCPMC11227498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.